DRUG SUPPORT OF RADIONUCLEAR THERAPY OF THYROID GLAND MEDULLAR CANCER

Buchman V., Drobot L., Dzhuzha D.A., Nechay O.P.

According to the protocol of the European Association of Nuclear Medicine 22 patients with have been treated with 131I-MIBG. Control monitoring with 99mТс-carbomec all patients underwent 6 monthes after the radionuclide treatment. The paper reports the effi- cacy of 131I-MIBG-therapy. Outcomes of long-term ob- serving of these patients are analyzed. It has been proved that the radionuclide therapy and diagnostic improve ef- ficient of complex treatment and monitoring among pa- tients with medullar thyroid carcinoma.